glp 1 parkinson's disease and neuroprotection Glucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Diseases: A Comprehensive Review Glucagon-like peptide-1 (GLP-1) receptor agonists

At a plateau, the labeled option within the semaglutide family is a maintenance dosage decision rather than a second agent

Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved

Moreover, the BMSC-associated effect is inhibited by anti-MET antibodies

Dosage Form: Softgel Capsules